Rafferty Asset Management, LLC Cti Biopharma Corp Transaction History

Rafferty Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$4.2 - $6.01 $1.41 Million - $2.01 Million	-334,976 Reduced 22.77%	1,136,381 $4.77 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $1.68 Million - $2.33 Million	378,314 Added 34.61%	1,471,357 $8.84 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $3.51 Million - $4.87 Million	655,442 Added 149.78%	1,093,043 $6.36 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $1.55 Million - $2.74 Million	437,601 New	437,601 $2.61 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.